Patrick Orestes de Azevedo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patrick Orestes de Azevedo has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Ricardo Tostes Gazzinelli
Centro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
3 shared publications - Benedito Antônio Lopes da Fonseca
Universidade de São Paulo, Brazil
2 shared publications - Luiz Tadeu Moraes Figueiredo
Centro de Pesquisa em Virologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
2 shared publications - Luiza Antunes Castro-Jorge
Virology Research Center, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil
2 shared publications - Marcilio Jorge Fumagalli
Laboratory of Molecular Immunology, The Rockefeller University, New York, USA
2 shared publications - Marcos Gontijo da Silva
Graduate Program in Biotechnology, Federal University of Tocantins, Gurupi 77425-000, TO, Brazil
2 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by MDPI AG in Future Pharmacology
- Vol. 6 (3) , 50
Therapeutic Potential of Microbial Exopolysaccharides in Skin Wound Healing: A Systematic Review and Meta-Analysis of In Vivo Experimental Studies in Rat Models
Background/Objectives: Microbial exopolysaccharides (EPS) are complex biopolymers that mimic the native extracellular matrix and have emerged as promising biomaterials for tissue regeneration. Methods: This study aimed to evaluate the therapeutic potential of microbial EPS in the healing of cutaneous wounds through a systematic review and meta-analysis of in vivo experimental studies in rat models. Conducted in accordance with the PRISMA guidelines, a search of the Scopus, Embase, and ScienceDirect databases identified 2496 records. After rigorous screening, 17 rat studies were included in the quantitative synthesis, comprising 181 animals and 398 wounds (199 treated with EPS and 199 controls). Results: Treatment with EPS promoted a mean healing rate of 90.46% (range: 9.1% to 100%) on day 14, reflecting the heterogeneity of the included studies. The meta-analysis revealed an overall mean difference of 21.15% (95% CI: 17.89 to 24.42; p < 0.0001) in favor of EPS compared with the control group. Conclusions: These findings support the potential for translating EPS-based therapies from rodent models to human wounds, although the substantial heterogeneity of the evidence and the absence of clinical data indicate that controlled clinical trials remain essential to validate their application in humans.
- 10 September 2026
- Published by MDPI AG in Future Pharmacology
- Vol. 6 (3) , 50
Open AccessTherapeutic Potential of Microbial Exopolysaccharides in Skin Wound Healing: A Systematic Review and Meta-Analysis of In Vivo Experimental Studies in Rat Models
Background/Objectives: Microbial exopolysaccharides (EPS) are complex biopolymers that mimic the native extracellular matrix and have emerged as promising biomaterials for tissue regeneration. Methods: This study aimed to evaluate the therapeutic potential of microbial EPS in the healing of cutaneous wounds through a systematic review and meta-analysis of in vivo experimental studies in rat models. Conducted in accordance with the PRISMA guidelines, a search of the Scopus, Embase, and ScienceDirect databases identified 2496 records. After rigorous screening, 17 rat studies were included in the quantitative synthesis, comprising 181 animals and 398 wounds (199 treated with EPS and 199 controls). Results: Treatment with EPS promoted a mean healing rate of 90.46% (range: 9.1% to 100%) on day 14, reflecting the heterogeneity of the included studies. The meta-analysis revealed an overall mean difference of 21.15% (95% CI: 17.89 to 24.42; p < 0.0001) in favor of EPS compared with the control group. Conclusions: These findings support the potential for translating EPS-based therapies from rodent models to human wounds, although the substantial heterogeneity of the evidence and the absence of clinical data indicate that controlled clinical trials remain essential to validate their application in humans.
- Open Access
- 20 July 2026
- Published by MDPI AG in Preprints.org
Risk Factors and Clinical Profile of IgM Anti-Toxoplasma gondii-Positive Pregnant Women in the Eastern Brazilian Legal Amazon: Lessons for Prenatal Screening
Background: To evaluate the sociodemographic and clinical profiles of pregnant women with positive IgM anti‑T. gondii in the eastern Brazilian Legal Amazon, during the period from 2018 to 2023. Methods: This was an indirect observational study through the retrospective analysis of 1,049 medical records from pregnant women attended in the Obstetrics service of Basic Health Units. The dependent variable was the presence of IgM antibodies, and the independent variables included age brackets, ethnicity, schooling, occupation, and clinical complaints. Data were analyzed using Epi‑Info 3.3.2 software. Risk factors and odds ratio (OR) with 95% CI were calculated. Results: From the 1,049 medical records analyzed, 52 (4.97%) presented IgM anti‑T. gondii antibodies. There was a significant correlation between IgM presence and age older than 30 years (OR 2.17; CI: 1.60–7.12), being employed (OR: 8.42; CI: 1.05–22.12), being married (OR: 3.02; CI: 1.43–9.32), and having less than eight years of schooling (OR: 3.04; CI: 1.24–11.56). Conclusions: The prevalence of IgM antibodies in the studied population was considered high, associated with low schooling, employment, and age over 30 years. The asymptomatic characteristic of acute infection is highlighted, reinforcing the need for effective prenatal screening.
- 20 July 2026
- Published by MDPI AG in Preprints.org
Open AccessRisk Factors and Clinical Profile of IgM Anti-Toxoplasma gondii-Positive Pregnant Women in the Eastern Brazilian Legal Amazon: Lessons for Prenatal Screening
Background: To evaluate the sociodemographic and clinical profiles of pregnant women with positive IgM anti‑T. gondii in the eastern Brazilian Legal Amazon, during the period from 2018 to 2023. Methods: This was an indirect observational study through the retrospective analysis of 1,049 medical records from pregnant women attended in the Obstetrics service of Basic Health Units. The dependent variable was the presence of IgM antibodies, and the independent variables included age brackets, ethnicity, schooling, occupation, and clinical complaints. Data were analyzed using Epi‑Info 3.3.2 software. Risk factors and odds ratio (OR) with 95% CI were calculated. Results: From the 1,049 medical records analyzed, 52 (4.97%) presented IgM anti‑T. gondii antibodies. There was a significant correlation between IgM presence and age older than 30 years (OR 2.17; CI: 1.60–7.12), being employed (OR: 8.42; CI: 1.05–22.12), being married (OR: 3.02; CI: 1.43–9.32), and having less than eight years of schooling (OR: 3.04; CI: 1.24–11.56). Conclusions: The prevalence of IgM antibodies in the studied population was considered high, associated with low schooling, employment, and age over 30 years. The asymptomatic characteristic of acute infection is highlighted, reinforcing the need for effective prenatal screening.
- Open Access
- 13 February 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-17
Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
The current COVID-19 vaccines protect against severe disease, but are not effective in controlling replication of the Variants of Concern (VOCs). Here, we used the existing pre-clinical models of severe and moderate COVID-19 to evaluate the efficacy of a Spike-based DNA vaccine (pCTV-WS) for protection against different VOCs. Immunization of transgenic (K18-hACE2) mice and hamsters induced significant levels of neutralizing antibodies (nAbs) to Wuhan and Delta isolates, but not to the Gamma and Omicron variants. Nevertheless, the pCTV-WS vaccine offered significant protection to all VOCs. Consistently, protection against lung pathology and viral load to Wuhan or Delta was mediated by nAbs, whereas in the absence of nAbs, T cells controlled viral replication, disease and lethality in mice infected with either the Gamma or Omicron variants. Hence, considering the conserved nature of CD4 and CD8 T cell epitopes, we corroborate the hypothesis that induction of effector T-cells should be a main goal for new vaccines against the emergent SARS-CoV-2 VOCs.
- 13 February 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-17
Open AccessDifferential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
The current COVID-19 vaccines protect against severe disease, but are not effective in controlling replication of the Variants of Concern (VOCs). Here, we used the existing pre-clinical models of severe and moderate COVID-19 to evaluate the efficacy of a Spike-based DNA vaccine (pCTV-WS) for protection against different VOCs. Immunization of transgenic (K18-hACE2) mice and hamsters induced significant levels of neutralizing antibodies (nAbs) to Wuhan and Delta isolates, but not to the Gamma and Omicron variants. Nevertheless, the pCTV-WS vaccine offered significant protection to all VOCs. Consistently, protection against lung pathology and viral load to Wuhan or Delta was mediated by nAbs, whereas in the absence of nAbs, T cells controlled viral replication, disease and lethality in mice infected with either the Gamma or Omicron variants. Hence, considering the conserved nature of CD4 and CD8 T cell epitopes, we corroborate the hypothesis that induction of effector T-cells should be a main goal for new vaccines against the emergent SARS-CoV-2 VOCs.
- Open Access
CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant
The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals.
Open AccessCoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant
The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals.
- Open Access
Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization
The persistent circulation of SARS-CoV-2 represents an ongoing global threat due to the emergence of new viral variants that can sometimes evade the immune system of previously exposed or vaccinated individuals. We conducted a follow-up study of adult individuals that had received an inactivated SARS-CoV-2 vaccine, evaluating antibody production and neutralizing activity over a period of 6 months. In addition, we performed mice immunization with inactivated SARS-CoV-2, and evaluated the immune response and pathological outcomes against Gamma and Zeta variant infection. Vaccinated individuals produced high levels of antibodies with robust neutralizing activity, which was significantly reduced against Gamma and Zeta variants. Production of IgG anti-S antibodies and neutralizing activity robustly reduced after 6 months of vaccination. Immunized mice demonstrated cellular response against Gamma and Zeta variants, and after viral infection, reduced viral loads, IL-6 expression, and histopathological outcome in the lungs. TNF levels were unchanged in immunized or not immunized mice after infection with the Gamma variant. Furthermore, serum neutralization activity rapidly increases after infection with the Gamma and Zeta variants. Our data suggest that immunization with inactivated WT SARS-CoV-2 induces a promptly responsive cross-reactive immunity response against the Gamma and Zeta variants, reducing COVID-19 pathological outcomes.
Open AccessProtective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization
The persistent circulation of SARS-CoV-2 represents an ongoing global threat due to the emergence of new viral variants that can sometimes evade the immune system of previously exposed or vaccinated individuals. We conducted a follow-up study of adult individuals that had received an inactivated SARS-CoV-2 vaccine, evaluating antibody production and neutralizing activity over a period of 6 months. In addition, we performed mice immunization with inactivated SARS-CoV-2, and evaluated the immune response and pathological outcomes against Gamma and Zeta variant infection. Vaccinated individuals produced high levels of antibodies with robust neutralizing activity, which was significantly reduced against Gamma and Zeta variants. Production of IgG anti-S antibodies and neutralizing activity robustly reduced after 6 months of vaccination. Immunized mice demonstrated cellular response against Gamma and Zeta variants, and after viral infection, reduced viral loads, IL-6 expression, and histopathological outcome in the lungs. TNF levels were unchanged in immunized or not immunized mice after infection with the Gamma variant. Furthermore, serum neutralization activity rapidly increases after infection with the Gamma and Zeta variants. Our data suggest that immunization with inactivated WT SARS-CoV-2 induces a promptly responsive cross-reactive immunity response against the Gamma and Zeta variants, reducing COVID-19 pathological outcomes.
- 1 October 2021
- Published by Elsevier in Acta Tropica
- Vol. 222, 106021
Phenotypic, functional and serological aspects of genotypic-specific immune response of experimental T. cruzi infection
- 1 October 2021
- Published by Elsevier in Acta Tropica
- Vol. 222, 106021
Phenotypic, functional and serological aspects of genotypic-specific immune response of experimental T. cruzi infection